Gregory P Bisson, MD, MSCE
Associate Professor of Medicine (Infectious Diseases)
Senior Scholar, Department of Biostatistics and Epidemiology, Perelman School of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
832 Blockley Hall
423 Guardian Drive
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, PA 19104-6021
423 Guardian Drive
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania
Philadelphia, PA 19104-6021
Office: 215-573-5811
Fax: 215-573-5315
Fax: 215-573-5315
Education:
BA (Japanese)
University of Wisconsin-Madison, 1992.
MD
University of Minnesota School of Medicine, 1997.
MSCE (Epidemiology)
Perelman School of Medicine, University of Pennsylvania, 2006.
Permanent linkBA (Japanese)
University of Wisconsin-Madison, 1992.
MD
University of Minnesota School of Medicine, 1997.
MSCE (Epidemiology)
Perelman School of Medicine, University of Pennsylvania, 2006.
Description of Research Expertise
My research is dedicated to improving treatment outcomes of patients with HIV and tuberculosis (TB) and other AIDS-associated opportunistic infections. Current research projects are evaluating the relationship between very early virologic and immunologic response to antiretroviral therapy and clinical outcomes in adults with HIV/TB. Many patients with advanced HIV die soon after antiretroviral therapy initiation, and our research group focuses on trying to understand the pathophysiologic and social mechanisms underlying these early deaths. In addition, we are pursuing translational projects evaluating novel host-directed therapies for treatment of drug resistant TB.Selected Publications
Winters N, Schnitzer ME, Campbell JR, Ripley S, Winston C, Savic R, Ahmad N, Bisson G, Dheda K, Esmail A, Gegia M, Monedero I, Dalcolmo MP, Rodrigues D, Singla R, Yim JJ, Menzies D.: Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment. PLoS One 18(10): e0292106, Oct 2023.Araújo-Pereira M, Krishnan S, Salgame P, Manabe YC, Hosseinipour MC, Bisson GP , Damocles PS, Rouzier S, Leong S, Mave V, Kipyego Sawe F, Siika AM , Kanyama C, Dadabhai SS, Lama JR, Valencia-Huamani J, Badal-Faesen S, Lalloo UG, Naidoo N, Mohapi L, Kityo C, Andrade B , Gupta A: Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial. EClinical Medicine 60(102030), June 2023.
Maenetje P, Baik Y, Schramm D, Vangu MDT, Wallis RS, Mlotshwa M, Tiemessen CT, Li Y, Kornfeld H, Churchyard G, Auld SC, Bisson GP : Circulating biomarkers, FeNO, and lung function in patients with HIV and tuberculosis. J Infect Dis In Press, 2023.
Labuda SM, Seaworth B, Dasgupta S, Goswami ND, Haley C, Ashkin D, Hatsengate D, Cropper T, Semidey AC, Darnall E, Macias P, Jasuja S, Wegner P, Landers K, Yu S, Soukup J, Narita M, DeSilva M, Armitige L, Corriveau E, Schechter M, Bisson GP, Sanchez A, Cummins J, Lindsey JA, Easton AV, Dworkin FF, Nilsen D, Lardizabal AA: Bedaquiline, pretomanid, and linezolid with or without moxifloxacin. Lancet Respiratory Diseases 2023.
Gupta A, Sun X, Krishnan S, Matoga M, Pierre S, Mcintire K, Faesen L, Kityo C, Dadabhai S, Naidoo K, Samaneka W, Lama J, Veloso V, Vidya Mave, Lalloo U, Langat D, Hogg L, Bisson GP, Kumwenda J, Hosseinipour M, for the ACTG A5274/REMEMBER Study Team: Isoniazid adherence reduces mortality and incident tuberculosis at 96 weeks among adults initiating antiretroviral therapy with advanced HIV in multiple high burden settings. Open Forum Infectious Diseases July 2022.
Mehta K, Narayanan N, Heysell S, Bisson GP, Subbian S, Kurepina N, Kreiswirth, BN, Vinnard C : Pharmacogenetic variability and the probability of pharmacodynamic target attainment during tuberculosis meningitis treatment: a physiologically based pharmacokinetic modeling approach. Tuberculosis 2022 Notes: In press.
Baik Y, Maenetje P, Schramm D, Tiemessen C, Ncube I, Churchyard G, Wallis R, Vangu M, Kornfeld H, Li Y, Auld S, Bisson GP: Lung function and collagen 1a levels are associated with changes in six-minute walk test distance during treatment of TB among HIV-infected adults: a prospective cohort study BMC Pulmonary Medicine 2022 Notes: In press.
Matoga M, Bisson GP, Gupta A, Miyahara S, Sun X, Manabe YC, Kumwenda J, Malawi B, Kanyama C, Nyirenda M, Ngongondo M, Mbewe A, Moi DL, Wallis C, Mugerwa H, Hosseinipour MC, on behalf of the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team: Urine LAM Testing in Advanced HIV-Infected Adults in a Trial of Empiric TB Therapy Clin Infect Dis 73(4): e870-e877, Aug 2021.
Krishnan S, Queiroz A, Guptal A, Gupte N, Bisson GP, Kumwenda J, Naidoo K, Mohapi L, Mave V, Mngqibisa R, Lama JR, Hosseinipour MC, Andrade BB, and Karakousis PC, on behalf of the ACTG A5274 REMEMBER NWCS 414 Study Team : Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Frontiers in Immunology Jun 2021.
Auld SC, Kornfeld H, Maenetje P, Mlotshwa M, Chase W, Vangu MT, Torigian, DA, Wallis RS, Churchyard G, Bisson GP: Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis. BMC Pulmonary Medicine 21(1), Jan 2021.